These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 8391144)
1. Inhibition of DNA topoisomerases by sanguiin H-6, a cytotoxic dimeric ellagitannin from Sanguisorba officinalis. Bastow KF; Bori ID; Fukushima Y; Kashiwada Y; Tanaka T; Nonaka G; Nishioka I; Lee KH Planta Med; 1993 Jun; 59(3):240-5. PubMed ID: 8391144 [TBL] [Abstract][Full Text] [Related]
2. Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity. Habermeyer M; Fritz J; Barthelmes HU; Christensen MO; Larsen MK; Boege F; Marko D Chem Res Toxicol; 2005 Sep; 18(9):1395-404. PubMed ID: 16167831 [TBL] [Abstract][Full Text] [Related]
3. [Poisons of DNA topoisomerases I and II]. Charcosset JY; Soues S; Laval F Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034 [TBL] [Abstract][Full Text] [Related]
4. Interaction of DNA intercalator 3-nitrobenzothiazolo (3,2-a)quinolinium with DNA topoisomerases: a possible-mechanism for its biological activity. Báez A; Riou JF; Le Pecq JB; Riou G Mol Pharmacol; 1990 Mar; 37(3):377-82. PubMed ID: 2156151 [TBL] [Abstract][Full Text] [Related]
5. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
6. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Goldwasser F; Bae I; Fornace AJ; Pommier Y Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795 [TBL] [Abstract][Full Text] [Related]
7. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure. Danks MK; Pawlik CA; Whipple DO; Wolverton JS Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557 [TBL] [Abstract][Full Text] [Related]
8. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol. Adlakha RC; Ashorn CL; Chan D; Zwelling LA Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251 [TBL] [Abstract][Full Text] [Related]
9. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Mattern MR; Mong SM; Bartus HF; Mirabelli CK; Crooke ST; Johnson RK Cancer Res; 1987 Apr; 47(7):1793-8. PubMed ID: 3028614 [TBL] [Abstract][Full Text] [Related]
10. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. Utsugi T; Mattern MR; Mirabelli CK; Hanna N Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396 [TBL] [Abstract][Full Text] [Related]
11. Evidence for the participation of topoisomerases I and II in cadmium-induced metallothionein expression in Chinese hamster ovary cells. Mattern MR; Tan KB; Zimmerman JP; Mong SM; Bartus JO; Hofmann GA; Drake FH; Johnson RK; Crooke ST; Mirabelli CK Anticancer Drug Des; 1989 Aug; 4(2):107-24. PubMed ID: 2478139 [TBL] [Abstract][Full Text] [Related]
12. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine. Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224 [TBL] [Abstract][Full Text] [Related]
13. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Kapoor R; Slade DL; Fujimori A; Pommier Y; Harker WG Oncol Res; 1995; 7(2):83-95. PubMed ID: 7579731 [TBL] [Abstract][Full Text] [Related]
14. SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin. Horie K; Tomida A; Sugimoto Y; Yasugi T; Yoshikawa H; Taketani Y; Tsuruo T Oncogene; 2002 Nov; 21(52):7913-22. PubMed ID: 12439742 [TBL] [Abstract][Full Text] [Related]
15. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex. Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981 [TBL] [Abstract][Full Text] [Related]
16. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. Lelièvre S; Benchokroun Y; Larsen AK Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278 [TBL] [Abstract][Full Text] [Related]
17. Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity. Labourier E; Riou JF; Prudhomme M; Carrasco C; Bailly C; Tazi J Cancer Res; 1999 Jan; 59(1):52-5. PubMed ID: 9892183 [TBL] [Abstract][Full Text] [Related]
18. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage. Marx G; Zhou H; Graves DE; Osheroff N Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Ishida R; Miki T; Narita T; Yui R; Sato M; Utsumi KR; Tanabe K; Andoh T Cancer Res; 1991 Sep; 51(18):4909-16. PubMed ID: 1654205 [TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability. Kong XB; Rubin L; Chen LI; Ciszewska G; Watanabe KA; Tong WP; Sirotnak FM; Chou TC Mol Pharmacol; 1992 Feb; 41(2):237-44. PubMed ID: 1311406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]